Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma 51Lymphoma, Follicular 36Leukemia, Lymphocytic, Chronic, B-Cell 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Lymphoma, Non-Hodgkin 29Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Mantle-Cell 23Leukemia 23Lymphoma, Large-Cell, Immunoblastic 20Hodgkin Disease 18Burkitt Lymphoma 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 12Multiple Myeloma 12Neoplasms, Plasma Cell 9Leukemia, Myeloid, Accelerated Phase 9Myeloproliferative Disorders 8Leukemia, Myeloid, Chronic-Phase 8Congenital Abnormalities 8Waldenstrom Macroglobulinemia 7Recurrence 7Blast Crisis 7Lymphoma, T-Cell, Cutaneous 6Primary Myelofibrosis 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Dendritic Cell Sarcoma, Interdigitating 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, Large-Cell, Anaplastic 4

Interventions

thymoglobulin 1sargramostim 1ruxolitinib 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Tacrolimus 1Rituximab 1Observation 1Mycophenolic Acid 1Monatide (IMS 3015) 1Methotrexate 1Melphalan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Cyclophosphamide 1Clofarabine 1Busulfan 1Bone Marrow Transplantation 1Blood Specimen Collection 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × sargramostim × Lymphoid × Clear all
NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Sellas Life Sciences Group

Phase 2 Completed
22 enrolled 8 charts
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡